ANI Pharmaceuticals, Inc.

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement between the parties.

globenewswire.com - 2026-07-16 16:34:00

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, a condition the company abbreviated as chronic NIU-PS.

proactiveinvestors.com - 2026-07-13 12:55:34

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic...

proactiveinvestors.com - 2026-07-13 08:46:00

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).

globenewswire.com - 2026-07-13 06:50:00

The executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000. The transaction represented 2% of the insider's total direct equity holdings in the company.

fool.com - 2026-07-12 20:20:17

An ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026. The sale represented 1.58% of Carey's direct holdings, reducing his direct stake to 177,543 shares post-transaction.

fool.com - 2026-07-09 17:36:46

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-02 10:46:08

ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.

seekingalpha.com - 2026-06-26 10:26:34

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-16 10:46:03

ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.

zacks.com - 2026-06-10 14:30:30

ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.

zacks.com - 2026-06-10 14:26:04

ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company's defining investment narrative.

zacks.com - 2026-06-10 14:21:17

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-29 10:46:14

PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows:

globenewswire.com - 2026-05-27 06:50:00

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.

zacks.com - 2026-05-15 12:51:17

ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.

zacks.com - 2026-05-15 12:47:07

Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.

zacks.com - 2026-05-15 12:40:57

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-13 10:51:12

ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.

fool.com - 2026-05-11 17:09:29

ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.

zacks.com - 2026-05-11 12:31:30

ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.

marketbeat.com - 2026-05-08 16:07:05

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 12:51:21

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-08 10:31:15

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.7 per share a year ago.

zacks.com - 2026-05-08 09:05:48

PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026.

globenewswire.com - 2026-05-08 06:50:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-06 10:45:32

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

zacks.com - 2026-05-04 10:56:20

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-05-01 11:00:19

Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

zacks.com - 2026-04-28 10:43:36

Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.

zacks.com - 2026-04-27 13:20:56

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-04-27 13:11:20

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

zacks.com - 2026-04-27 09:55:13

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-04-24 10:51:44

PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.

globenewswire.com - 2026-04-24 06:50:00

ANI Pharmaceuticals rides Cortrophin Gel's surge to anchor 2026 growth, with rising guidance and new initiatives positioning the specialty portfolio for continued momentum.

zacks.com - 2026-04-20 11:20:22

ANI Pharmaceuticals trades at 10x forward earnings with a $93 target, but execution in Cortrophin and ophthalmology recovery may decide if the discount closes.

zacks.com - 2026-04-20 11:20:21

ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.

zacks.com - 2026-04-20 11:20:19

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-04-20 10:45:44

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®.

globenewswire.com - 2026-04-20 06:50:00

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

zacks.com - 2026-04-17 13:46:07

The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com - 2026-04-17 10:55:29

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

zacks.com - 2026-04-16 13:01:08

SUBCY, MKSI, ANIP, AHKSY and ADSK have been added to the Zacks Rank #1 (Strong Buy) List on April 16, 2026.

zacks.com - 2026-04-16 07:01:07